Batts DH. Linezolid-a new option for treating gram-positive infections; 2000. p. 23–9.
Google Scholar
Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health Syst Pharm. 2002;59:2413–25.
Article
CAS
PubMed
Google Scholar
Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695–8.
Article
PubMed
Google Scholar
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60:1361–9.
Article
CAS
PubMed
Google Scholar
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(SUPPL. 4):7–15.
Google Scholar
Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–42.
Article
CAS
PubMed
Google Scholar
MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother. 2003;51:17ii–25.
Article
Google Scholar
Choi GW, Lee J-Y, Chang MJ, Kim YK, Cho Y, Yu YM, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124:228–34.
Article
CAS
PubMed
Google Scholar
Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019;63(8):e00605–19.
Article
CAS
PubMed
PubMed Central
Google Scholar
Giunio-Zorkin N, Brown G. Real-life frequency of new-onset thrombocytopenia during linezolid treatment. Can J Hosp Pharm. 2019;72:133–8.
PubMed
Google Scholar
Kim HS, Lee E, Cho YJ, Lee YJ, Rhie SJ. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J Clin Pharm Ther. 2019;44:84–90.
Article
CAS
PubMed
Google Scholar
Lima LS, Brito EDCA, Mattos K, Parisotto EB, Perdomo RT, Weber SS. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. Hematol Transfus Cell Ther. 2020;42:230–7.
Article
PubMed
Google Scholar
Richards GA, Brink AJ. Therapeutic drug monitoring: linezolid too? Crit Care. 2014;18:525.
Article
PubMed
PubMed Central
Google Scholar
Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pea F, Viale P, Cojutti P, Del pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034–42.
Article
CAS
PubMed
Google Scholar
Alsultan A. Determining therapeutic trough ranges for linezolid. Saudi Pharm J. 2019;27:1061–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411–23.
Article
CAS
PubMed
Google Scholar
Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 2021;21:1–15.
Article
Google Scholar
Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69:1881–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Higgins J. Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). 2011. http://training.cochrane.org/handbook.
Google Scholar
Holger S, Jan B, Gordon G, Andrew O. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (Updated October 2013). 2013. https://gdt.gradepro.org/app/handbook/handbook.html
Google Scholar
Dong HY, Xie J, Chen LH, Wang TT, Zhao YR, Dong YL. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33:1029–35.
Article
CAS
PubMed
Google Scholar
Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, et al. Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. Chemotherapy. 2014;59:319–24.
Article
Google Scholar
Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012;44:60–4.
Article
CAS
PubMed
Google Scholar
Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36:795–9.
Article
CAS
PubMed
Google Scholar
Jones SJ, Nichols KR, DeYoung HL, Cox EG, Knoderer CA. Linezolid-associated thrombocytopenia in children with renal impairment. J Pediatric Infect Dis Soc. 2015;4:272–5.
Article
PubMed
Google Scholar
Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345–51.
Article
CAS
PubMed
Google Scholar
Moraza L, Leache L, Aquerreta I, Ortega A. Linezolid-induced haematological toxicity. Farm Hosp. 2015;39:320–32.
PubMed
Google Scholar
Plachouras D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K, et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis. 2006;43:e89–91.
Article
CAS
PubMed
Google Scholar
Rabon AD, Fisher JP, MacVane SH. Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. Ann Pharmacother. 2018;52:1162–4.
Article
PubMed
Google Scholar
Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17:382–7.
Article
CAS
PubMed
Google Scholar
Wu V-C, Wang Y-T, Wang C-Y, Tsai I-J, Wu K-D, Hwang J-J, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Int J Antimicrob Agents. 2006;28:345–51.
Article
CAS
PubMed
Google Scholar
Han X, Wang J, Zan X, Peng L, Nie X. Risk factors for linezolid-induced thrombocytopenia in adult inpatients. Int J Clin Pharm. 2022;44:330–8.
Article
CAS
PubMed
Google Scholar
Hsu Y-C, Chen S-Y, Hung Y-J, Huang Y-W. Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients. Sci Rep. 2022;12:9894.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kawasuji H, Tsuji Y, Ogami C, Kimoto K, Ueno A, Miyajima Y, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22:13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Komatsu T, Nakamura M, Uchiyama K, Inoue G, Sakanoue K, Kawamura A, et al. Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia. J Chemother. 2022;34:375–80.
Maray I, Rodríguez-Ferreras A, Álvarez-Asteinza C, Alaguero-Calero M, Valledor P, Fernández J. Linezolid induced thrombocytopenia in critically ill patients: risk factors and development of a machine learning-based prediction model. J Infect Chemother. 2022;28:1249–54.
Article
CAS
PubMed
Google Scholar
Qin Y, Liu Y, Chen Z, Cao M, Shen Y, Ye Y. A risk factor-based predictive model for linezolid-induced anaemia: a 7-year retrospective study. J Clin Pharm Ther. 2021;46:1591–9.
Article
CAS
PubMed
Google Scholar
Sato Y, Iguchi M, Kato Y, Morioka H, Hirabayashi A, Tetsuka N, et al. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days. Nagoya J Med Sci. 2020;82:407–14.
CAS
PubMed
PubMed Central
Google Scholar
Thirot H, Briquet C, Frippiat F, Jacobs F, Holemans X, Henrard S, et al. Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers. Antibiotics. 2021;10(5):530.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu F, Zhang X-S, Dai Y, Zhou Z-Y, Zhang C-H, Han L, et al. Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients. Front Pharmacol. 2022;13:844567.
Kosaka T, Kokufu T, Shime N, Sugioka N, Kato R, Hamaoka K, et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients. Int J Antimicrob Agents. 2009;33:368–70.
Article
CAS
PubMed
Google Scholar
Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, et al. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics. J Infect Chemother. 2014;21:70–3.
Article
PubMed
Google Scholar
Alffenaar JWC, Van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AMA, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet. 2010;49:559–65.
Article
CAS
PubMed
Google Scholar
Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother. 2007;51:379–82.
Article
CAS
PubMed
Google Scholar
NCT00396084, National Institute of A, Infectious D. Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis. 2006. http://clinicaltrials.gov/show/NCT00396084.
Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57:1144–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58:2334–43.
Article
PubMed
PubMed Central
Google Scholar
Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475–80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eslam RB, Burian A, Vila G, Sauermann R, Hammer A, Frenzel D, et al. Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. J Clin Pharmacol. 2014;54:1058–62.
Article
CAS
PubMed
Google Scholar
Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45:1843–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luque S, Grau S, Alvarez-Lerma F, Ferrández O, Campillo N, Horcajada JP, et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014;44:409–15.
Article
CAS
PubMed
Google Scholar
Myrianthefs P, Markantonis SL, Vlachos K, Anagnostaki M, Boutzouka E, Panidis D, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50:3971–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010;66:291–8.
Article
CAS
PubMed
Google Scholar
Traunmüller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnagl E, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents. 2010;36:84–6.
Article
PubMed
Google Scholar
Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother. 2015;70:198–206.
Article
CAS
PubMed
Google Scholar
Cojutti PG, Merelli M, Bassetti M, Pea F. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. J Antimicrob Chemother. 2019;74:3588–95.
Article
CAS
PubMed
Google Scholar
Fang J, Chen C, Wu Y, Zhang M, Zhang Y, Shi G, et al. Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?—experience from a prospective observational study. Ann Transl Med. 2020;8:493.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luque S, Muñoz-Bermudez R, Echeverría-Esnal D, Sorli L, Campillo N, Martínez-Casanova J, et al. Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity. Ther Drug Monit. 2019;41:732–9.
Article
CAS
PubMed
Google Scholar
Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242–7.
Article
CAS
PubMed
Google Scholar
Morata L, Cuesta M, Rojas JF, Rodriguez S, Brunet M, Casals G, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother. 2013;57:1913–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128–33.
Article
CAS
PubMed
Google Scholar
Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17:70–5.
Article
CAS
PubMed
Google Scholar
Alffenaar J-WC, Kosterin JGW, van Altena R, van der Werf TS, Uges DRA, Proost JH. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010;32:97–101.
Article
CAS
PubMed
Google Scholar
Blackman AL, Jarugula P, Nicolau DP, Chui SH, Joshi M, Heil EL, et al. Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2021;65(2):e01619–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47:1824–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians?. Int J Antimicrob Agents. 2016;48(6):728–31 S0924857916302783. https://doi.org/10.1016/j.ijantimicag.2016.08.023.
Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179–81.
Article
CAS
PubMed
Google Scholar
Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136–45.
CAS
PubMed
Google Scholar
Alici G, Valerio M, Munoz P, Alcala L, Xandra Garcia G, Burillo A, et al. Crossm systematic therapeutic drug monitoring. Antimicrob Agents Chemother. 2017;61:1–6.
Google Scholar
Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48:728–31.
Article
CAS
PubMed
Google Scholar
Pea F, Cojutti P, Dose L, Baraldo M. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2016;81:341–8.
Article
CAS
PubMed
Google Scholar
Shi C, Xia J, Ye J, Xie Y, Jin W, Zhang W, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:464–75.
Article
CAS
PubMed
Google Scholar